VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

D. Yue,W. Wang,H. Liu, Q. Chen, C. Chen, L. Liu, P. Zhang, G. Zhao,F. Yang,G. Han,Y. Cheng, B. Yu, Y. Yang, H. Chen, J. Jiang,B. Yao, S. Wang, R. Wang, W. Zheng, C. Wang

Annals of Oncology（2024）

引用 1|浏览47